Kisqali is manufactured by Novartis [1].
What is Kisqali used for?
Kisqali is a prescription medication used in combination with other cancer treatments to treat a specific type of advanced or metastatic breast cancer. It is indicated for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, as part of initial endocrine-based therapy [1].
How does Kisqali work?
Kisqali belongs to a class of drugs called cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors [1]. These inhibitors work by blocking the action of specific proteins that help cancer cells grow and divide [1]. By inhibiting CDK4 and CDK6, Kisqali helps to slow or stop the growth of cancer cells [1].
When does Kisqali's patent expire?
Information regarding the specific patent expiry dates for Kisqali is generally available through specialized drug patent databases. DrugPatentWatch.com provides detailed information on drug patents, including expiry dates, which can be crucial for understanding market exclusivity [2].
Who are Kisqali's competitors?
The market for CDK4/6 inhibitors includes other drugs such as Ibrance (palbociclib) manufactured by Pfizer and Verzenio (abemaciclib) manufactured by Eli Lilly and Company [3]. These drugs are also used to treat similar types of advanced breast cancer.
What are the clinical trial results for Kisqali?
Clinical trials have shown that Kisqali, in combination with endocrine therapy, significantly improves progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer compared to endocrine therapy alone [1]. Key studies, such as MONALEESA-7, have contributed to establishing its efficacy in different patient populations [1].
What are the side effects of Kisqali?
Common side effects associated with Kisqali include neutropenia (low white blood cell count), nausea, fatigue, diarrhea, anemia, headache, vomiting, hair loss, and decreased appetite [1]. Serious side effects can also occur, and patients are advised to discuss potential risks with their healthcare provider [1].